A new cancer risk assessment test, developed by Renatech Co. Ltd. Is now available in Tokyo's Shinjuku district. The test, called "Metal Balance Test," requires only 6 milliliters of blood and aims to evaluate an individual's cancer risk. The service is being offered by Shijo Internal Medicine, starting from October.
The test analyzes blood samples to detect imbalances in metal levels, which are believed to be linked to cancer development. Renatech, a health technology company, has partnered with local clinics to provide this innovative service. Patients can now book appointments from October onwards, marking the first step in a broader initiative to improve early cancer detection.
The company emphasizes that the test is non-invasive and can be completed quickly. It is part of a growing trend in personalized medicine, where early detection plays a crucial role in treatment outcomes. No further details on the accuracy or cost of the test were provided.
The introduction of this test reflects increasing investment in health technology in Japan, with a focus on preventive care and early diagnosis.
